Abera and Orexo partner for vaccine powder formulations
Abera Bioscience and Orexo have entered a partnership to develop and test the powder formulations of the former’s vaccine candidates…
Infectious Diseases
-
-
AIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapy
Immuno-pharma company AIM ImmunoTech has secured a patent from the Netherlands Patent Office for its RNA product candidate, Ampligen (rintatolimod),…
-
UK reports near eradication of meningitis C amid declining vaccine uptake
New data from the UK Health Security Agency (UKHSA) indicates significant progress in combating meningitis caused by meningococcal group C…
-
Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech
Gilead Sciences has bolstered its position as a leader in the HIV research space by purchasing an investigational HIV vaccine…
-
KM Biologics’ mpox vaccine approved for emergency use by WHO
The World Health Organization (WHO) has listed KM Biologics' mpox vaccine for emergency use, marking the second shot approved by…
-
Bavarian Nordic shares sink by 12% after mpox sales slump in Q3
Bavarian Nordic has already secured a sizeable portion of revenue for 2025 through orders for its mpox/smallpox vaccine, but financial…
-
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its…
-
IDWeek 2024: strategic approaches and challenges in mpox vaccination
At IDWeek 2024 in Los Angeles, California, recent updates on mpox (formerly known as monkeypox) were discussed. Significant advancements and…
-
Matinas BioPharma mulls wind-down as antifungal therapy deal falls through
Matinas BioPharma has halted all product development activities and fired 80% of its staff, including three members of senior management,…
-
Spero’s stock slides after antibiotic flops in Phase II trial
Spero Therapeutics has suspended the development of its antibiotic SPR720, after the therapy failed to meet the primary endpoint in a Phase…
